Allogene Therapeutics Inc (ALLO)’s Market Momentum: Closing Strong at 2.29, Down -0.43

Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Allogene Therapeutics Inc’s stock clocked out at $2.29, down -0.43% from its previous closing price of $2.30. In other words, the price has decreased by -$0.43 from its previous closing price. On the day, 1.13 million shares were traded. ALLO stock price reached its highest trading level at $2.32 during the session, while it also had its lowest trading level at $2.22.

Ratios:

To gain a deeper understanding of ALLO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.25 and its Current Ratio is at 12.25. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.17.

On May 31, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $11.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 18 ’24 when MESSEMER DEBORAH M. sold 18,641 shares for $2.28 per share. The transaction valued at 42,488 led to the insider holds 166,765 shares of the business.

Humer Franz B sold 11,200 shares of ALLO for $26,181 on May 30 ’24. The Director now owns 255,253 shares after completing the transaction at $2.34 per share. On May 16 ’24, another insider, Belldegrun Arie, who serves as the Director of the company, bought 1,724,137 shares for $2.90 each. As a result, the insider paid 4,999,997 and bolstered with 1,724,137 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 478866464 and an Enterprise Value of 128447368. For the stock, the TTM Price-to-Sale (P/S) ratio is 5320.69 while its Price-to-Book (P/B) ratio in mrq is 0.93. Its current Enterprise Value per Revenue stands at 1976.113 whereas that against EBITDA is -0.501.

Stock Price History:

Over the past 52 weeks, ALLO has reached a high of $5.78, while it has fallen to a 52-week low of $2.01. The 50-Day Moving Average of the stock is -10.92%, while the 200-Day Moving Average is calculated to be -29.18%.

Shares Statistics:

It appears that ALLO traded 2.84M shares on average per day over the past three months and 1771120 shares per day over the past ten days. A total of 209.11M shares are outstanding, with a floating share count of 136.83M. Insiders hold about 34.53% of the company’s shares, while institutions hold 66.99% stake in the company. Shares short for ALLO as of 1722384000 were 37750648 with a Short Ratio of 13.30, compared to 1719532800 on 41384695. Therefore, it implies a Short% of Shares Outstanding of 37750648 and a Short% of Float of 25.419999999999998.

Most Popular